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There isampleevidence thatmost idiotypicdeterminants (idiotopes)are associated
with complementarity-determining regions (CDRs) 1 of Ig molecules . For example,
some, although not all, interactions between idiotopesand anti-idiotopes areblocked
by the ligand of the antibody expressing the idiotope (1, 2) . Idiotopes whose interac-
tions are not blocked by ligand are sometimes referred to as framework idiotopes .
However, because the interaction with ligandmay notinvolve allof theCDRresidues
of the antibody, even an idiotope that is not blocked by ligand may include amino
acid residues in CDRs . The high degree of individual specificity ofmany anti-Id
antibodies argues for an essential contribution of CDRs (3-6) .
There is little information on the dimensions ofidiotopes . Chemical modification
studies andcorrelations withamino acid sequence variations in families ofantibodies
of a given specificity have implicated particular amino acid side chains, usually in
CDRs, as being part of idiotopes (7). In general, such studies demonstrate that a
particular modification or amino acid substitution results in loss of reactivity with
anti-idiotype . Such loss could be induced, even if the modification or substitution
involved only a smallpart of an idiotope, such as asingle amino acid . The structural
change could result ina significantdecrease in the attractive forces between idiotope
and anti-idiotope or in steric interference . Such a modification might also induce
structural alterations at a different site ; i.e ., the side chain involved might not be
part ofthe idiotope affected . Despite these limitations, useful information concerning
the localization of idiotopes has been obtained by careful studies of this type. In
the anti-p-azobenzenearsonate (anti-Ar)system an extensive study to mapidiotopes
was carried outbyJeske et al . (8) . Theirwork implicated specific residues in hyper-
variable regions in reactivity with each of several anti-idiotypic mAbs .
A possibility suggested by Alzari et al . (9) is that the area of contact of idiotope
and anti-idiotope may in general be comparable with that observed in the interac-
tion between an epitope ofa protein antigen with a specific mAb. In two instances
inwhich interactions with protein antigens have been analyzed by X-ray crystallog-
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raphy (10, 11), the area of contact has ranged between 700 and 800 A2; a similar
area of contact was estimated for a third antiprotein antibody (12). These dimen-
sions correspond roughly to 25-307o of the entire surface area of an antibody com-
prising the six CDRs. It was found in each study that amino acid side chains present
in most or all of the CDRs make contact with the epitope of the protein antigen
and that few contacts are made with framework residues.
The idiotype investigated in the present report, designated CRIA, is associated
with a large proportion of anti-Ar antibodies induced in strain A mice by immuni-
zation with the Ar conjugate of keyhole limpet hemocyanin (13, 14). The results
are consistent with the view that some idiotopes of crossreactive idiotype A (CRIA)
occupy a large proportion of the surface of an anti-Ar antibody that comprises the
CDRs. Our analysis was facilitated by the recent determination of the three-
dimensional structure of an A/J anti-Ar mAb, R19.9, whose V segment and L
chain are very similar to those of CRIA+ anti-Ar antibodies (15).
Materials and Methods
mAbs.
￿
A summary of properties of mAbs used is given in Table I. The CRIA' mAbs 6-16
and CB9 show no differences in their partial V region nucleotide sequences from the un-
mutated VH36-65 germline sequence (21, 22); VH36-65 and its somatic mutants are be-
lieved to encode the V region of all CRIA' antibodies (22). R16.7, which is strongly CRIA',
exhibits three amino acid differences in its V segment (positions 1-98), as compared with
the sequence encoded by VH36-65 (Table I). R19.9 has a V segment and L chain sequence
similar to that encoded by VH36-65. It is however, CRIA-, probably because of the large
size of its D region (11 amino acids as compared with eight in canonical CRIA' sequences).
CRID' mAbs have V segments correspondingto that associated with CRIA; However, GRID
differs markedly from CRIA in its D region (Table I) and L chain; the latter corresponds
to the L chain of another idiotypic family, CRIA (20).
TABLE I
Properties of mAbs Used
" All mAbs are of A/J origin except AD8 (rat mAb). Amino acid sequences were deduced from mRNA
sequencing.
t Positions of amino acid substitutions as compared with the sequence encoded by the VH36-65 germline
gene (21,22); the V regions of both CRIA and CRID are encoded by this gene (19).
s Number of amino acid residues.
I Positions 56-98 of V have been determined for this sample. Some ofthe sequences have a small num-
ber of ambiguities (maximum of five).
I E. M. Rosen and A. Nisonoff, unpublished results.
"" P. F. Robbins and A. Nisonoff, unpublished results.
mAb" Idiotype
V amino acid
sequence
Positions of
substitutions)
Length of D
segments Reference
6-16 (IgGlx) CRIA 56-9811 None 8
CB9 (IgGlx) CRIA 50-98 None 8 '"
R16.7 (IgGlrc) CRIA 1-98 51,56,85 8 16
93G7 (IgGlrc) CRIA 1-98 58,59 8 17
SE20.2 (IgErc) CRIA 1-98 58,59 8 18
R19.9 (IgG26ic) - 16-98 34,55,58,59,74 11 15
All (IgG2bx) CRID 27-98 None 1 19
SM1 .5 (IgMx) CRID 40-98 63 1 19
DE2 (IgMic) CRID 27-98 None 1 19
S27 (IgGlrc) CRIC 1-98 Not applicable 1 20
AD8 (Rat IgG2aic) (anti-CRIA V)HABA ET AL.
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A cell line producing mAb AD8 was the generous gift of Dr. Peter Hornbeck (23). AD8
reacts strongly with anti-Ar antibodies of A/J mice and of allotype-congenic C.AL-20 mice,
but not with anti-Ar antibodies of several unrelated strains tested, including BALB/c and
C57BL/6. AD8 reacts to a significant degree with normal A/J IgG (23) and with H chains
of CRIA' antibodies on a Western blot in the absence of L chains (24). AD8 also reacts
strongly with members of the CRID family, which share V with CRIA but differ greatly
in their D and VL regions (19). Thus, AD8 appears to be V-specific.
Separation andRecombination of HandL Chains.
￿
Nonspecific IgG or an IgG mAb was re-
duced with 0.01 M dithiothreitol (Calbiochem-Behring Corp., LaJolla, CA) for 1 h at room
temperature in Tris buffer, pH 8.0 (25). Thiol groups were then blocked with 0.06 M iodo-
acetamide (Sigma Chemical Co., St. Louis, MO), recrystallized from hot water. After dial-
ysis against neutral Tris buffer, guanidine hydrochloride was added to the reduced and alkylated
protein to a concentrationof 7 M, pH 7.4 (26). The mixture, containing 10-20 mg ofprotein,
was immediately passed over a 150-cm3 column of Sephacryl S-200 equilibrated with 5 M
guanidine hydrochloride, pH 6.5, to separate H and L chains. The use of Sephacryl rather
than Sephadex substantially reduces the time required for gel filtration (to 3-4 h). In each
case two separate peaks were obtained. Recombinants were prepared immediately after gel
filtration, usingan approximately equimolar ratio of H and L chains. The mixture was then
dialyzed extensively against borate-saline buffer, pH 8. In several instances the product was
concentrated, passed over a column of Sephacryl S-300 in neutral buffer, and the protein
in the major peak collected. In each case >80% of the protein was present in a single peak,
which corresponded in its elution volume to that of intact IgG. When autologous chains de-
rived from a given CRIA' antibody were recombined, the idiotypic activity recovered was,
in each case, close to that of the intact molecule (see Results).
Assayfor CRIB Activity.
￿
This assay was carried out as previously described (19), using 10
ng of 1211-labeled R16.7 as the ligand and sufficient rabbit anti-CRIA to bind N60% of the
labeled ligand. To provide carrierprotein, the mixture also contained 311 ofrabbit anti-OVA
antiserum and 7,ul ofnormal AKR ascitic fluid. Complexes were precipitated with an excess
of goat anti-rabbit IgG that had been adsorbed with mouse Ig-Sepharose. The idiotype in
unlabeled test samples was quantified by determining the amount required to cause 5070
inhibition ofbinding ofthe labeled R16.7. Variations ofthis assay were carried out with other
'III-labeled ligands (mAb CB9, All, or HcegLN), and with a different anti-Id preparation
(rabbit anti-6-16). The subscript N refers to nonspecific IgG.
Direct binding assays were carried out in a similar manner using varying amounts ofanti-
Id and a constant weight of labeled ligand; complexes were precipitated as above. In some
instances direct binding assays were used to ascertain the total idiotype-binding capacity of
an anti-Id preparation for a given ligand. Such assays were run with a constant levelof anti-Id
and increasing amounts of '251-labeled ligand, and the plateau level of ligand binding was
determined. When mAb AD8 (rat IgG2aK) was used as anti-Id reagent, immune complexes
were precipitated with mouse antirat IgG. The mice used to prepare the antirat IgG were
(BALB/c x C57BL/6)Fi . A/J mice were not used because they express the AD8 idiotope
in their normal Ig (23).
Rabbit Anti-IdAntibodies.
￿
Anti-Id was prepared against affinity-purified A/J anti-Ar anti-
bodies by two inoculations of 500 p.g in CFA followed by monthly inoculations of 500 t~g
in IFA. Rabbits were bled repeatedly starting 1 wk after the third inoculation. Pooled an-
tiserum was adsorbed exhaustively with normal A/J Ig conjugated to Sepharose 4B. Rabbit
anti-Id against the anti-Ar mAb 6-16 (CRIA') was prepared similarly; however, the antiserum
was adsorbed with normal AKR Ig-Sepharose and S27-Sepharose. The AKR strain differs
in H chain allotype from A/J and also appears to be deficient in the L chain required for
CRIA expression (27). mAb S27 is CRIc' ; its V and VL regions therefore differ markedly
from those of CRIA' antibodies (20). The purpose of using these adsorbents for anti-6-16
was to leave unadsorbed any anti-Id antibodies specific for the V or VL regions.
Results
Idiotypic Activity of Hybrid Molecules Containing HcRIA and L Chains from Different
Sources.
￿
Table II presents data on inhibitorycapacities ofintact molecules, or mole-107 8
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TABLE II
Inhibitory Capacities of Intact and Recombined Molecules in the Assayfor CRIA
Assays used rabbit anti-CRIA antibodies with long 12'I-labeled R16.7 (CRIA*) as ligand .
* Numbers in parentheses indicate percent inhibition by the weight of inhibitor specified.
$ Recombined molecules. The subscript N refers to nonspecific A/J IgG . Other subscripts refer
to the mAb that provided the H or L chain.
cules containing recombined H and L chains, in the assay for CRIA using labeled
R16.7 as ligand. 12-14 ng of unlabeled CRIA+ mAb (R16.7, 6-16, or CB9) caused
50% inhibition in the assay. For the autologous CRIA+ recombinant molecule,
HCBgLCB9, 17 ng was required; i.e., its idiotypic activity was nearly as great as that
ofintact CB9 (14 ng required for 50°Io inhibition). For hybrid molecules containing
H chains from a CRIA+ mAb (CB9) and nonspecific L chains (LN), 250 ng was re-
quired for 50% inhibition. This could be accounted for by a low affinity of HcBgLN
or by -7 To contamination (17/250) of HCB9 by LCB9. The low inhibitory capacities
of HCB9LA11 or HCBgLS27 suggest that the actual contamination was 3% or less (mAb
All and S27 are GRID and CRIc, respectively). L chains from R19.9 were about
as effective as L chains from CB9 in restoring idiotypic activity to HCB9. This is
consistent with previous data showing that R19.9, which is CRIA- , expresses L
chains that are idiotypically very similar to L chains of CRIA (28), and are nearly
identical in sequence to that encoded by the VK1o germ line gene, which encodes
the L chains of CRIA+ molecules (15, 29).
The high recovery of activity in the homologous recombinant, HCBgLCB9, indi-
cates that the method used for separating and recombining H and L chains did not
disrupt idiotypic determinants. We observed a similarly high retention of idiotypic
activity when H and L chains of the GRID' mAb All or of the CRIc+ mAb S27
were separated and recombined (data not shown).
Absence ofAnti-idiotypic Antibodies with Significant Binding Affinityfor CRIA-derived L
Chains. The inhibition data in Table II demonstrate that molecules containing
CRIA-derived L chains but H chains from other sources are very weak inhibitors
in the assay for CRIA; these molecules are HNLCB9, HAIILCB9, and HS27LCB9 . In
Inhibitor
Amount required
for 50% inhibition Inhibitor
Amount required
for 50% inhibition
ng ng
A/J IgG >3,000 (6)' HCB9LN 250
R16.7 (CRIA) 13 HCB9LCB9 17
6-16 (CRIA) 12 HCBgL19.9 19
CB9 (CRIA) 14 HCB9LA11 570
R19.9 >3,000 (11) HCB9LS27 620
All (CRID) >3,000 (17)
S27 (CRIc) >3,000 (8) HA11LN >3,000 (23)
HA11LCB9 1,250
HNLN' >3,000 (6) HA11L19.9 >3,000 (23)
HNLCB9 2,050 HS27LN >3,000 (4)
HNL19.9 >3,000 (9) HS27Lcs9 1,850
HNLA11 >3,000 (7) H19.9LN >3,000 (2)
HNLS27 >3,000 (3) H19.9LCB9 630
Ht9.9L19.9 >3,000 (8)addition, intact R19.9, which has CRIA-related L chains (see above), is an extremely
poor inhibitor; 3,000 ng caused 11 17o inhibition. That the absence of activity in L
chains is notdueto denaturation during therecombination experiments is supported
by the poor inhibitory activity of intact R19.9, and by the almost complete recovery
of idiotype activity in HCB91.,CB9.
The requirementfor appropriate L chains to provide good inhibition in the assay
for CRIA is in agreement with previous studies (e.g., reference 5). This does not,
however, exclude the possibility that some anti-Id antibodies react well with L chains
alone. If, for example, 10% of the anti-Idpopulation were specific forL chains alone,
a maximum of 10°Io inhibition in the CRIA assay could be achieved by molecules
containing appropriate L chains but inappropriate H chains.
To explore the possibility of direct binding of L chains, we measured the binding
of 1111-labeled molecules containing LcRIA by alarge excess of anti-Id. The data are
presented in Figs. 1 and 2. It is evidentthat there was virtuallyno detectable binding
of labeled HNLCB9, even by a large excess of rabbit anti-Id antibodies directed ei-
ther against amity-purified A/J anti-Ar serum antibodies (anti-CRIA) or against
the strongly CRIA+ mAb 6-16. In addition, the bindingcapacity of each anti-Id re-
agent for R19.9, which has L chains characteristic of CRIA, wasextremely low. The
ratios of amounts of antiserum required for 50% binding of labeled R19.9 or CB9
(CRIA') were 70:1 and 210:1, respectively, for anti-CRIA and anti-6-16(Id). These
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FIGURE 1..
￿
Measurements ofdirect bind-
ingof a series of 1211-labeledligands. The
anti-Id (anti-CRIA) was prepared in a
rabbit against affinity-purified A/Janti-Ar
antibodies. Complexes were precipitated
with goat anti-rabbit Fc (of IgG). In all
bindingassays 10 ng oflabeled ligandwas
used (except Fig. 4, in which increasing
amounts of ligand were used).
FIGURE 2.
￿
Same as Fig. 1, except that the
rabbit anti-Idwasprepared against mAb
6-16.1080
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ratios are minimal as an indication of lack of specificity for L chains alone because
the VH region of R19.9 is structurally related to that of CRIA+ antibodies (15); i.e.,
some of the slight binding of R19.9 may be attributable to V. It is evident that
a negligible proportion of anti-Id antibodies has appreciable affinity for L chains.
Nevertheless, as indicated by the abovedata on inhibition by recombined molecules
(e.g., HcB9LN vs. HCBgLCB9), L chains contribute greatly to the formation of most
idiotypic determinants.
Anti-Id Antibodies with Specificity for H Chains. For the reasons indicated in dis-
cussing Lchains, it is difficult, from the data on inhibition, to assess the proportion
of anti-Id antibodies having specificity for H chains; i.e., that react effectively with
H chains in theabsenceofappropriate Lchains. As suggested above, the interpreta-
tion of data on inhibition would be complicated by any contamination of HCRIA
with LCRIA; such contamination would result in strong inhibition when large
amounts were tested. The problem of, say, 10°Jo contamination is much less serious
when direct binding of anti-Id to a labeled HCRIA-containing preparation is mea-
sured; a maximum of 10% couldbe bound. We therefore carried out direct binding
measurements on labeled HL recombinant molecules.
Therelevant data are shown in Figs. 1 and 2, which present results obtained with
anti-CRIA, and anti-6-16(Id), respectively. Each curve was obtained by using an 1251_
labeled ligand and increasing amounts of anti-Id. It is evident, first, that high per-
centages of recombinants containing HCB9 and inappropriate L chains (HcB9LN or
HCB9LS27) were bound when sufficiently high concentrations of either anti-Id anti-
body were used. These high percentages cannot be explained by a small degree of
contamination of HCB9 with residual LCB9 . An approximation of the proportion of
anti-HCB9 in the anti-Id antibodies can be made by comparing the amounts of anti-
Id required to bind 50% of the maximal levels of HcB9LN or HCB9LS27 with the
amounts required to bind 50°Io of the maximal level of the CRIA+ mAb, CB9. For
anti-CRIA(Fig. 1) the ratios are 2.7 :1 and 4.1 :1 for HcB9LN and HCB9LS27, respec-
tively. For anti-6-16(Id) the corresponding ratios are 5.7:1 and 6.7 :1 . These ratios
will of course be affected by the affinities of the interactions. However, the actual
proportion of anti-Id reactive with H chain alone probably equals or exceeds that
indicated by the direct binding data, because one would not expect to elicit many
antibodies with higher affinity for H chain than fortheintact molecule by immunizing
with the intact molecule. It is evident then that, in contrast to L chains, a significant
fraction (-15-37%) of anti-Id antibodies are reactive with H chains. Nevertheless,
these data on direct binding, as well as the inhibition data in Table II, concur in
indicating that the majority ofanti-Id antibodies interact most effectively with mol-
ecules containing both chains.
Evidencefor the Presence ofAnti-Id Antibody whose Interaction with H Chains Is not En-
hancedby L Chains. Despitethe effective interaction of anti-Idwith Hchains (recom-
bined with inappropriate L chains), the possibility remainsthat even those antibody
molecules that react with H chains react better with the intact molecule. Experi-
ments to address this question were carried out as follows. We labeled HcB9LN with
1251 and added sufficient anti-Id (anti-CRIA or anti-6-16) to bind 50-60% of the
labeled ligand. Complexes were precipitated with a second antibody (see Materials
and Methods). Variousunlabeledmoleculeswere tested as inhibitors ofthe primary
interaction. The data in Fig. 3, A and B indicate that, with either anti-Id, HcB9LNz
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or HCBgLS27 were about as effective as inhibitors as the intact CRIA+ mAbs, CB9
or 6-16. This indicates that most anti-Id molecules that do bind HCBgLN do so with
an affinity comparable with that with which they interact with the intact idiotype
molecule. Ifthe anti-Idmolecules involved in this interaction hadrelatively low affinity
for HCBgLN or HCBgLS27, the unlabeled hybrid molecules wouldhave been poor in-
hibitors as compared with CB9 or 6-16. Since 50-60% of the labeled ligand was
bound in the absence of inhibitor, a few-percent contamination of HCB9 by LCB9
could not have influenced the results significantly.
Saturation Binding Experiments to Determine Reactivity ofAnti-Id with HChain.
￿
The
experiments of Fig. 4 represent an alternative approach to the percentage of anti-
CRIA antibodies that have specificity for the Hchain alone. Those direct binding
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FIGURE 3.
￿
Inhibition assays; unlabeled inhibi-
tors are specified on the graphs. (A) Experiments
used rabbit anti-CRIA with 1211-labeled HCBgLcv
as ligand. (B) Rabbit anti-Id(6-16) wasused with
1251-labeled HCBgLN as ligand. The amount of
anti-Id used in A and B was sufficient to bind
50-60% of the labeled ligand.
FIGURE 4.
￿
Saturationbindingassays using increas-
ing amountsofthe six different 1251-labeled ligands
specified on the graph and0.6 A,1 ofadsorbed anti-6-
16(Id). Immune complexes were precipitated as in
Fig. 1.1082
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experiments utilized aconstant amount of anti-6-16(Id) and increasing amounts of
1251-labeled idiotype. The data in Fig. 4 indicate that the binding capacity of anti-
6-16(Id) for HCB9LN is 32 or 35 17o as great as its binding capacity for intact 6-16
or CB9. The corresponding percentages are 19 and 21% for HCBgLs27. 6-16 and CB9
are CRIA'; S27 is CRIC' and has L chains unrelated to those ofCRIA' antibodies.
Thus, in good agreement with the data obtained with a constant amount of ligand,
-20-35% of the anti-Id antibodies are reactive with HCRIA combined with "inap-
propriate" L chains.
Anti-IdAntibodies Speckfor the V  Segment.
￿
The experiments described above in-
dicate the presence in anti-CRIA or anti-6-16(Id) of antibodies reactive with HCRIA;
the latter of course includes V, D, andJH segments. We tried to ascertain whether
the V,, segment alone interacts effectively with some of the anti-Id molecules pre-
pared against intact CRIA' antibody. Because it is difficult to isolate VH segments,
we used an indirect approach that takes advantage of the GRID class of A/J anti-Ar
antibodies. Anti-Ar mAbs expressing GRID contain a germline-encoded VH seg-
ment apparently identical in amino acid sequence to that of CRIA, but with a much
shorterDregion, comprising one amino acid residue as compared with eightresidues
in CRIA (19). The VL segment in CRID appears identical to that of another idio-
typic family of anti-Ar antibodies (CRIc) and differs markedly from the VL seg-
ments of CRIA (19, 20). Our approach, then, was to ascertain the extent of reac-
tivity of anti-CRIA with CRID+ mAbs on the assumption that such crossreactivity
would be directed largely to the VH segment.
The validity of this approach depends on the idiotypic similarity of the V seg-
ment when present in a CRID+ or CRIA ' molecule. Despite identity of amino acid
sequences, it is of course possible that the nonidentity of surrounding regions, in-
cluding D and VL, could alter the interaction of V with anti-Id reagents. Data sup-
porting the idiotypic similarity will be described later.
Direct Binding of A11 by Anti-CRIA or Anti-6-16(Id).
￿
Figs. 1 and 2 show that the
CRID' mAb All is bound by anti-CRIA or by anti-6-16(Id) but that the interac-
tion is much weaker than that for intact CRIA' mAb. For example, the amount of
anti-6-16(Id) required to bind 50oJo of labeled mAb All was -25 times as great as
that required for mAb CB9. The interaction with All is also weaker than that with
hybrid molecules containing CRIA-derived H chains and inappropriate L chains
(HCBgLN or HCBgLs27). Small amounts of anti-Id bind about two to three times more
HCB9Ls27 or HCB9LN than All. When antibodies with specificity for HCB9LN were
examined (by using labeled HcBgLN as ligand), a similarly weak direct interaction
with All was observed (Fig. 3, A and B).
That All interacts with a smaller proportion of anti-6-16(Id) than CRIA' mAbs
or HCRIA-containing hybrids is also shown by the saturation binding experiments
of Fig. 4. The maximum degree )f binding of All was 15-16% of the values for
6-16 or CB9 and lower than that of either HCRIA-containing hybrid molecule.
Idiotypic Similarity of V H Present in CRIA and CRID.
￿
As already mentioned, the
anti-Id mAb AD8 reacts with VHDJ, and the reaction is independent of the L
chain. Theavailable data do not bear on thecontribution oftheD segment to reac-
tivity with AD8. The following experiments support the reactivity ofAD8 with Vt,
alone and suggest that this interaction is not influenced by theD region. They also
indicate that CRIA' and CRID' mAbs interact equally well with AD8.Fig. 5 shows results ofdirect binding experiments using various labeled ligands
and increasing amounts ofAD8. The binding curves forCRIA' mAbs 6-16 and CB9
are very similar. As indicatedinTable I, the V segments of6-16 and CB9 are iden-
ticaltothe germlineVH36-65 sequence in positions sequenced so far. Ofparticular
interest is the observation that All, SM1.5, and DE2 (all CRID') react as well or
better with AD8 than 6-16 and CB9 (both CRIA+), despite the large difference in
length of their D regions; in addition, AD8 was prepared against CRIA' antibodies.
The fact that CRID' mAbs bind as well as CRIA' mAbs to AD8 indicates that the
V segment is responsible for the binding and that any contributions ofthe D re-
gion and L chain are negligible. Thus, CRIA+ and CRID+ mAbs express the AD8-
reactive idiotope to a very similar degree.
The binding of AD8 to DE2 and SM1.5 (both GRID) appears to be somewhat
stronger than that to the CRID' mAb, All (as well as to the CRIA+ mAbs 6-16 or
CB9). This may reflect the fact that DE2 and SM1.5 are IgM whereasAll is IgG2b.
The polymeric structure ofIgM may favorbivalent attachment ofAD8 with a con-
sequent increase in avidity.
The recombinant molecule, HCB9Ls27, interacted strongly with AD8, providing
further evidence for the predominant role ofthe H chain in the interaction. mAbs
SE20.2 and R16.7, both ofwhich are strongly CRIA', were bound by AD8, but
relatively high concentrations ofAD8were required. The lower affinity may be cor-
related with amino acid substitutions in V (see Discussion).
Specificity ofAD8 as Assessed by Inhibition Measurements.
￿
Fig. 6 A shows dataon inhi-
bition ofbinding ofthe '21I-labeled CRIA' mAb, CB9, to AD8. Unlabeled CRIA'
mAbs CB9 and 6-16, the hybrid molecule HCB9Ls27, and All (CRID) yielded very
similar inhibition curves. These data support the direct binding measurements in
indicating that the specificity ofAD8 is directed to VH and not to the Dregion or
L chain, and that the VH segments in CRIA and CRID react to a similar degree
with AD8.
Although mAbs SE20.2, 93G7, and R16.7 (all CRIA*) are inhibitors ofthe in-
teractions, the amounts required aremuchgreaterthan thoseof6-16 and CB9. This
is in agreementwith the direct measurements ofbindingto AD8 made with SE20.2
andR16.7 andmaybe attributableto somaticmutations in CDR2 (see Discussion).
The inhibition data in Fig. 6 B were obtained with labeled mAb All (CRID')
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FIGURE 5.
￿
Direct bindingassays; same
as Fig. 1, except that mAbAD8(rat anti-
Id)wasused andcomplexeswere precipi-
tatedwith mouse antirat Ig. 125I-labeled
ligands: (0) DE2; (/) SM1.5; (x) All;
(A) 6-16; (") CB9; (O) HCB9Ls27; (0):
HCB9LCB9; (A) SE20.2; (+) R16.7. mAb
R19.9 was completely nonreactive.1084
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as ligand in place oflabeled CB9 (CRIA+). The very close similarity of the results
in Fig. 6, A and B are again consistent with the view that AD8 recognizes only V,
since All and CB9 are similar only within this segment.
Anti-CRIA Contains Antibodies that React Equally Well with CRIA and CRID.
￿
The data
inFigs. 1, 2, and 4indicate thatonlyasmallproportion ofrabbit anti-6-16(Id)reacts
with All (CRID), despite the shared VH segment. Inhibition data in Fig. 7 were
obtained by usingrabbit anti-6-16(Id) with 1251-labeledAll as ligand. The datashow
that All (CRID), CB9 (CRIA), and 6-16 (CRIA) reacted equally well with that small
subpopulation ofanti-6-16(Id) that binds All.
To summarize, results obtained with the CRID+ mh i- All indicate that only a
small proportion ofanti-CRIA (N15%; Fig. 4) reacts with V in the absence ofthe
four other CDRs associated with CRIA. However, the V ofregions ofCRIA+ and
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FIGURE 6.
￿
Inhibition assays; unlabeledinhibi-
tors are specified on the graphs. The amount of
anti-Id (mAb AD8) used was sufficient to bind
-50% of the labeled ligand. (A) The ligand is
1251-labeled mAb CB9 (CRIA'); (B) the ligand
is 1251-labeled mAb All (CRID').
FIGURE 7 .
￿
Inhibition assays; unlabeled in-
hibitors arespecifiedon thegraph. Theanti-
Id used wasanti-6-16(Id), affinity purified on
All-Sepharose. The ligand is 1251-labeled
mAb All (CRID'). In the absence of inhib-
itor, 64% of the labeled ligand was bound.HABA ET AL.
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GRID' mAbs interact virtually identically with mAb AD8 and with that small
proportion of anti-CRIA antibodies that recognize VH alone.
Discussion
The data reported here are consistent with the view (9)that some individual idio-
topes may comprise a large segment of that surface area of an antibody molecule
that comprises the six CDRs. X-ray crystallographic studies have shown that the
total surface of this region generally comprises -2,000 A2 and that the interaction
with a single epitopeoflysozyme or neuraminidase may involve direct contacts over
a substantial part of the surface (600-700 A2) and involve all or nearly all of the
CDRs of the antibody. Our results indicate that most idiotopes include amino acid
residues derived from a minimum of two CDRs.
Role of L Chains.
￿
The data indicate that anti-Id antibodies prepared against a
CRIA+ antibody contain a very small proportion of molecules with specificity for
L chains alone. This was shown by the failure of anti-Id to bind hybrid molecules
containing LcxiA and H chains from other sources (Figs. 1 and 2). In addition, such
hybrid molecules were extremely poor inhibitors of the bindingofCRIA+ antibodies
to anti-CRIA (Table II). Also, mAb R19.9, whose L chains effectively reconstitute
CRIA when combined with HCRIA, was an extremely poor inhibitor of the binding
interactions of anti-CRIA. The poor inhibition by the hybrid molecules containing
appropriate L chains is consistent with results obtained in other idiotypic systems
(5, 30-32). The direct bindingmeasurements appear more relevant to this question
because hybrid molecules would be weak inhibitors even if, say, 10-20% of the anti-
Id were directed exclusively to the L chain. The maximum degree ofinhibition would
be 10-20% under such circumstances; nevertheless, polyclonal anti-Id specific for
L chain alone could still bind a very large proportion of labeled hybrid molecules
when sufficient anti-Id wastested in adirect bindingassay. However, no such binding
was detected.
Despite the apparent absence of anti-Id activity directed to Lchains alone, the L
chains play an important role in theformation of alarge proportion of the idiotypic
determinants. This is shown by the much greater inhibitory capacity in idiotype
assays of recombined molecules HCBgLCB9, as compared with HCB9Lr1, HCB9Ls27,
or HCB9LA11 . The observations on direct binding and inhibition can be reconciled
if one considers the relationship of the free energy of binding to the equilibrium
constant forthe association with anti-Id. If the L chain contributed, say, 4 kcal/mol
to the energy of interaction, this would correspond to a contribution of -103 M-1
to the association constant (Ka) value; this would account for the very poor compe-
tition by H chains in the absence of the appropriate L chain. In addition, the Ka
of anti-Id for the L chain would be -103 M-1 , a value too low to permit effective
direct binding by concentrations of antibody available for testing.
The observation that most anti-Id antibodies requireboth the H and L chain for
effectiveinteraction demonstrates that at leasttwo CDRregions, andpossibly more,
are required for effective binding.
Interaction ofAnti-Idwith H Chains.
￿
The data in Figs. 1, 2, and 4 show that some
of the anti-Idantibodies are reactive with H chains in the presence ofinappropriate
L chains (e.g., HcBgLlv). From the saturation binding curves (Fig. 4), using in-
creasing amounts of labeled ligand and a constant level of anti-Id, we found that1086
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-20-35% of the anti-Id is reactive with such molecules. These percentages cannot
be accounted for on the basis of contamination of HCRIA with LCRIA. The very low
inhibitory capacities of HCBgLAIi and HCB9LS27 in the assay for CRIA (Table II) in-
dicated that the degree of contamination of HCRIA with LCRIA was 3% or less.
The data on direct binding, which show that -70-80% of the anti-Id requires
both HCRIA and LCRIA for effective interaction, are consistent with inhibition data
in indicating that most anti-Id antibodies interact with CDRs from VL and VH.
Proportion of Anti-Id Reactive with the V H Segment.
￿
The results indicate that only
a small proportion of anti-CRIA reacts with the V segment (residues 1-98) in the
absence of the appropriate D and VL segments. Direct binding experiments (Figs.
1 and 2) show that a given amount of anti-Id binds -10% as much mAb All as
intact mAb CB9 (CRIA). All is a member of the CRID family, which shares the
V segment but not the D or VL segments with CRIA (19). Data indicating that
the V segments of CRIA and CRID are idiotypically very similar are discussed
below. The binding of All to anti-CRIA was also considerably weaker than the
binding of the H chain (HCBgLN or HCBgLS27 ; Fig. 1) . The relatively poor interac-
tion of Vt,, as compared with the entire H chain, was also demonstrated by the in-
hibition data in Fig. 3, A and B; mAb All was a poor inhibitor of the binding of
labeled HcB9LN to anti-CRIA (mAb CB9 is strongly CRIA+). These results indi-
cate that the most effective bindingto the H chain requires theD region in addition
to the VH segment; the D region comprises most if not all of the solvent-exposed
part of CDR3. The weak but significant interaction of the VH segment with anti-
CRIA is further evidence for a requirement for multiple CDRs for effective inter-
action with anti-CRIA.
The fact that mAb AD8 appears to recognize the VH segment alone (as shown
by its reactivity with H chains on Western blots [24] and its reactivity with CRID+
mAb) is not necessarily in conflict with the possibility that there is a large area of
contact between Id andanti-Id. AD8 mayinteract with regions of the molecule out-
side CDRs in addition to one or two CDRs in the VH segment. This would not
conflict with our observation that CRIA and CRID mAbs react almost identically
with AD8, since the two families share VH framework regions as well as CDRs. In
addition, it is not ruled out that AD8 reacts with some framework residues of the
L chain that might be common to CRIA and CRID .
The data indicate that nearly all anti-CRIA antibodies react with portions of both
VH and VL or with at least two CDR regions of the H chain. The areas of interac-
tion thus defined are minimal; antibodies reactive with H and L could interact with
several CDRs, and antibodies reactive with H chains might interact with all three
CDRs of the VH region. In addition, none of our data exclude additional interac-
tions with non-CDR (framework) regions of idiotype-bearing molecules. As long
as the hypervariable regions play a significant role in the interaction, additional in-
teractions with framework regions would not necessarily compromise the idiotypic
specificity of an anti-antibody. Our results are consistent with the possibility that
the interaction of an idiotope with anti-idiotope may take place over an area of con-
tact comparable with that observed for those epitopes on protein antigens that have
been described by X-ray crystallography (9-12). This question is being approached
by X-ray crystallographic analysis of Id-anti-Id complexes.
Evidencefor Retention ofStructure of CDR Loops in Different Environments.
￿
It is haz-HABA ET AL.
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ardous to generalize concerning constancy of the three-dimensional structure as-
sociated with a given CDR sequence in different environments. This question is
ofconsiderable interest, however, tothose who try to predict the three-dimensional
structure ofthe combining site ofan antibody from amino acid sequence data (e.g.,
33-39). The ability to make such predictions accurately could greatly increase our
understanding oftherelationship ofantibody structureto specificity, because ofthe
availability of many sequences and few crystallographic models.
Ofinterest in this regard is our observation that mAb AD8, which interacts with
the VH segment, appears to react almost identically with unmutated CRIA' and
CRID+ mAb, despite major differences in the D region (eight vs. one amino acid
residue) andL chain (19). This observation suggeststhatthe three-dimensional struc-
ture of CDR2 and/or CDR1 in V is not markedly perturbed by changes in the
other four CDRs ofthe molecule. This conclusion is in agreement with the fact that
V CDRl and CDR2 do not make close contacts with CDRs from VL and make
few contacts with VH CDR3 (15).
Another example ofconstancy of Id expression in a variety ofenvironments are
idiotypes present on subgroups of VK21 L chains, which can be identified, when
present in a variety of Ig molecules, by an anti-Id antiserum (38).
RelativeRolesofHandL Chairs inFormingIdiotopes.
￿
As already discussed, we found
that a fraction of anti-CRIA antibodies can bind H chains of the idiotype in the
absence of appropriate L chains, but were unable to demonstrate direct binding
to L chains in the absence ofCRIA-derived Hchains. A possible explanation comes
from the X-ray crystallographic study of the CRIA-related mAb R19.9. An anal-
ysis ofthe crystallographic model shows thattheCDRs ofthe Hchain offer alarger
area ofcontact than L chains in and around the central region ofthe CDR cluster.
In addition, somatic recombination mechanisms produce larger sequence variations
in H than in L chains, particularly in the D segment and its insertion points. A
high degree ofvariability would be expected to correlate with increased expression
of idiotypic determinants.
Residues in CDRsExposedtoAnti-Id.
￿
Examination ofthethree-dimensional struc-
ture of R19.9 (15) indicates that the following residues in CDRs are exposed and
capable of interacting with an anti-Id antibody: VH CDRI, 31 and 32; CDR2,
55-62; CDR3, 100-107; VL CDR1, 25-32; CDR2, 50-56; CDR3, 91-95. It is
noteworthy that each ofthe CRIA' mAbs we have studied that react poorly with
AD8 (which recognizes VH), and for which sequences are available, have one or
more substitutions from the germline-encoded mAb 36-65 in the VH 55-62 region
(Table I). These mAbs include R16.7, 93G7, and SE20.2, none ofwhichhas substi-
tutions in CDR1. R19.9 (CRIA related) has three substitutions in CDR2 and one
in CDR1 and does not react with AD8. Thus, loss ofreactivity with AD8 correlates
with substitutions in solvent-exposed areas. The data suggest strongly that AD8 in-
teractsdirectly with CDR2. Theunavailability ofmAbs withsubstitutions inCDRl
but not inCDR2 prevents conclusions concerning direct contact ofAD8with CDRl.
Additional Idiotypically Relevant Features ofthe Three-Dimensional Structure ofthe CDRs
of R19.9. As indicated, R19.9 has a VH region and L chain related to those of
CRIA but its D region is three residues longer (11 amino acids vs. 8). Some struc-
tural features of R19.9 CDRs, derived from X-ray analysis, are the following (15).
The only CDR ofthe Lchain that interacts with an Hchain CDRis CDR3, which1088
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contacts V CDR3. A contact is defined here by a distance of 4A or less. Gln89
Of VLCDR3 makes contacts with V TyA09. Contacts between the CDR3s are im-
portant for the assembly and interaction of V and VL regions (39, 40), and one
might predict that this region would often be part of an idiotope. VL CDR2 is ex-
posed the least of all CDRs at the combining site region and might be expected
to contribute little to the idiotypic structure. Thecombining site, a solvent-accessible
area of R19.9, is similar to that of other antibodies that have been studied and can
be estimated to be >2,000 A2. This large area offers many possibilities for Id-anti-
Id interactions, whichby analogywith the determined area of antigen-antibody con-
tacts might involve an area of -700-800 A2. All of the serological data on CRIA+
presented here are consistent with this possibility.
Summary
We have explored the structural basis ofidiotopes associated with the major idio-
type (CRIA) of A/J anti-;b-azobenzenearsonate antibodies, with emphasis on the
regions of contact with anti-idiotypic antibody. The analysis was facilitated by a re-
cent description of the three-demensional structure of the Fab portion of a CRIA-
related antibody molecule. Direct binding measurements failed to reveal idiotopes
associated exclusively with the L chain. However, the L chain participated in the
formation of -80% ofthe idiotopes recognized by polyclonal anti-Id. This indicates
that multiple complementarity-determining regions (CDRs) participate in the for-
mation ofidiotopes. Theaffinity of anti-IdforCDRs on Lchains must be appreciable
but insufficient to permit direct binding (i.e., less than -104 M-').
Approximately 20-35% of polyclonal anti-Id reacted with high affinity with H
chains recombined with non-CRIA-related L chains. This interaction was found to
involve the D region as well as one or both CDRs in the VH segment, again indi-
cating thecontribution ofmultiple CDRs. It is suggestedthat atypical idiotope may
be similarin size to that of protein epitopes whose three-dimensional structures are
known; such epitopes comprise a substantial fraction of the surface area occupied
by the CDRs of an antibody.
The expression of an idiotope recognized by the mAb AD8, which interacts with
the VH segment, was found to be unaffected by major changes in the neighboring
D and VL regions. This observation is relevant to efforts to predict three-dimen-
sional structure from the amino acid sequence of CRIA+ molecules.
Receivedfor publication 15 May 1989 and in revisedform 10 July 1989.
Note Addedin Proof: A recently completed study indicates that an anti-Id mAband its ligand,
an mAb to hen egg lysozyme, make contact over alarge proportion of the area ofthe CDRs
of the anti-Idantibody (Bentley, G. A., G. Boulot, R. J. Poljak, and M. M. Riottot, manu-
script in preparation).
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